Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC). This is ...

The Phase I trial — meaning it is the first in humans and had the goal of showing the therapy is safe — examined 12 patients with gastrointestinal cancers, including colon and rectal cancer.